SEP 20, 2020 3:30 PM PDT

New Drug Shows Promise in Treating Advanced COVID-19

WRITTEN BY: Annie Lennon

As the COVID-19 pandemic rages on, the search for drugs to combat the virus is ongoing. Now, scientists have found that a new drug, known as 4-Phenulbutiric acid (4-PBA), can modulate the body's inflammatory response to COVID-19 in animals. 

In the study, the authors note that the inflammatory process common in patients with severe cases of COVID-19 causes the release of cytokines- immune cells that then put the body's immune system into overdrive in what's known as a cytokine storm. Leading blood vessels to become extremely permeable, it often results in multiple organ failure and then death. As such, treating these cytokine storms is essential for managing the disease. 

Already, 4-PBA, under the name 'Buphenyl', is used as an anti-stress drug against other diseases that modulate cellular stress, including urea cycle disorders. As such, the researchers set out to see whether the drug could also be used to combat similar stress caused by COVID-19. 

From animal tests, the researchers confirmed that the treatment was able to 'fully curb mortality caused by respoirtory failure from cellular stress'. 

The researchers also managed to identify the endoplasmic reticulum resistant protein, 'Binding Immunoglobulin Protein' (BiP), a biomarker for cellular stress in the blood. They managed to do so by finding a correlation between high levels of the biomarker and inflammatory severity from COVID-19 infections. 

As such, the researchers say that BiP levels could both serve as an early indicator for how effective 4-BPA treatment may be, as well as to indicate groups at more risk of severe complications from COVID-19. 

"Therefore, if we know that the patient suffers from cellular stress, we can kill two birds with one stone - we can detect susceptibility before infection occurs and know how to treat it in due time," says co-author of the study, Ivan Duran, from the University of Malaga in Spain. 

 

Sources: Deccan HeraldFDA

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 07, 2020
Chemistry & Physics
Excipients: "Inactive" Drug Components Could Be Functioning Beyond Their Scopes
AUG 07, 2020
Excipients: "Inactive" Drug Components Could Be Functioning Beyond Their Scopes
Excipients are chemical additives to medications. They are incorporated into all kinds of pharmaceuticals to fulfil ...
AUG 25, 2020
Immunology
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
AUG 25, 2020
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
In a new study published in Cell, researchers have identified a metabolic enzyme that could have powerful tumor-killing ...
AUG 25, 2020
Drug Discovery & Development
The Potential of Antivitamins
AUG 25, 2020
The Potential of Antivitamins
What exactly are antivitamins? They are substances no less that have the power to target the biological function of a ge ...
SEP 19, 2020
Drug Discovery & Development
Novel Drug Delivery System for Neurological Diseases
SEP 19, 2020
Novel Drug Delivery System for Neurological Diseases
Scientists at Rutgers have developed a smart drug delivery system that targets inflammation in damaged nerves and helps ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
Loading Comments...